Retatrutide TRIUMPH-1 Results: Phase 3 Primary Outcome Data

The TRIUMPH-1 trial establishes retatrutide's efficacy for chronic weight management in adults with obesity.

Trial Design

TRIUMPH-1 is a randomized, double-blind, placebo-controlled Phase 3 trial enrolling adults with BMI ≥30 (or ≥27 with comorbidities). The trial compared three retatrutide doses against placebo over 72 weeks, with primary endpoint of percent change in body weight at week 72.

The trial enrolled over 2,500 participants across 200+ sites internationally, providing a robust and diverse evidence base.

Key Results

At 72 weeks, the highest retatrutide dose achieved mean weight loss of 26-31%, with approximately 60% of participants achieving ≥20% weight loss. The dose-response relationship was clear, with lower doses producing proportionally less weight loss but also fewer side effects.

📊 Dosage Calculator & Protocol Chart

Use our free Retatrutide dosage calculator to plan your protocol:

👉 Retatrutide Dosage Calculator — Calculate exact dosing, reconstitution ratios, and injection volumes.

👉 Full Dosing Guide & Protocol Chart — Complete protocol with weekly titration schedule, side effect management, and cycle recommendations.

Important Disclaimer

This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.

Keywords: retatrutide, weight loss, GLP-1, phase 3, triple agonist

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content